ReviewJournal of translational medicine2026
Myocardial fibrosis and glycolysis: a bibliometric study and visualization analysis (2000-2024).
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Exercise-mediated extracellular vesicle-derived non-coding RNAs and cardiovascular protection: mechanistic insights and bibliometric analysis.Frontiers in physiology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundMyocardial fibrosis represents a terminal pathological outcome in numerous cardiovascular diseases and is mechanistically linked to glycolytic dysregulation. However, systematic reviews integrating multidimensional evidence remain scarce.
objectiveThis study aims to conduct a visual analysis of myocardial fibrosis and glycolysis research using CiteSpace and VOSviewer, quantifying research trends and key contributors.
methodsLiterature on "myocardial fibrosis" and "glycolysis" published between January 1, 2000, and December 31, 2024, was retrieved from the Web of Science, PubMed, and Scopus databases. After deduplication, 408 articles were included for analysis. CiteSpace and VOSviewer were employed to analyze data regarding countries, institutions, authors, and keywords.
resultsA total of 408 studies were included. Annual publications on myocardial fibrosis and glycolysis exhibited a fluctuating upward trend, increasing from 1 (2000) to 51 (2024). These publications were divided into three phases: Initial Exploration (2000-2003, 1 article per year), Slow Fluctuation (2004-2009, 3-5 articles per year), and Rapid Development (2010-2024). During the Rapid Development phase, publications surged from 25 in 2019 to 44 in 2020, peaked in 2021-2022 (45 and 48 articles, respectively), and rebounded to 51 in 2024. Key contributors: The U.S. (177 studies, 32% of global output) and China (115 studies, 20%) were the leading contributors, collectively accounting for 52% of total publications; top institutions were Univ. of Alberta (15 Myocardial fibrosis representstudies) and Univ. of Utah (14 studies); core authors included Archer, S.L. (10 studies) and Chen, J.-X. (8 studies), with Lopaschuk, G.D. topping co-citations (117). High-frequency keywords: "heart failure" (107), "expression" (81), "metabolism" (60), "glycolysis" (44); high-centrality ones: "cardiac hypertrophy" (0.25), "fatty acid oxidation" (0.21). Emerging frontiers: "extracellular matrix" (burst intensity = 3.01, 2021-2024), "pulmonary hypertension" (3.61, 2022-2024). Clustering analysis identified 10 clusters (Silhouette Value = 0.7628, Modularity Q = 0.5292), including #0 pulmonary arterial hypertension (2014) and #10 mitochondrial dysfunction (2019).
conclusionOur bibliometric analysis reveals three pivotal trends: (1) The U.S. (32%) and China (20%) lead international collaborative networks; (2) Glycolytic reprogramming, oxidative stress, and metabolic interventions are prevalent research focuses; (3) Mitochondrial dysfunction and extracellular matrix remodeling are emerging frontiers. These findings clarify the glycolysis-fibrosis axis and provide a framework for targeted anti-fibrotic therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.